Sareum Holdings PLC

("Sareum" or the "Company")

Initiation of Toxicology Studies for Lead TYK2/JAK1 Inhibitor, SDC-1801

Cambridge, UK, 29 May 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce the initiation of a programme of toxicology studies for its lead TYK2/JAK1 inhibitor, SDC-1801.

The studies, designed to support longer-term dosing of SDC-1801, will investigate the general toxicology and potential of SDC-1801 to interact with other drugs. These are key regulatory requirements ahead of the planned Phase 2 clinical development programme, which is expected to focus initially on psoriasis. This marks an important step in advancing Sareum's autoimmune pipeline, following the successful completion of its Phase 1 clinical trial in healthy volunteers, which demonstrated a favourable safety and pharmacokinetic profile.

The toxicology studies required to prepare for Phase 2 clinical trials are being conducted at an established Contract Research Organisation and are expected to complete in Q4 2025. Sareum continues to make progress, in parallel, with its manufacturing and formulation optimisation activities to support the next stages of development.

Dr Stephen Parker, Executive Chairman of Sareum, commented: "We are pleased to have initiated this important package of toxicology studies for SDC-1801, which represents a significant milestone in the regulatory pathway towards Phase 2 trials. This progress reflects the encouraging data generated in our Phase 1 trial and our confidence in the potential of SDC-1801 as a differentiated treatment for autoimmune diseases. We look forward to providing further updates as we continue to advance this promising candidate."

- ENDS-

For further information, please contact: 

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

The Company has recently acquired the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com